Average Co-Inventor Count = 8.70
ph-index = 2
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Merck Sharp + Dohme Corp. (15 from 2,405 patents)
2. Msd R&d (China) Co., Ltd. (3 from 10 patents)
3. Msd R&d Co., Ltd. (0 patent)
15 patents:
1. 11970479 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
2. 11655216 - Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use
3. 11149036 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
4. 10961215 - N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use
5. 10933056 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
6. 10894775 - Piperidine derivatives as liver X receptor beta agonists, compositions, and their use
7. 10752587 - Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use
8. 9663506 - Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
9. 9636337 - Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
10. 9227971 - Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
11. 8927562 - Fused tricyclic inhibitors of mammalian target of rapamycin
12. 8901142 - Fused tricyclic compounds as mTOR inhibitors
13. 8703784 - Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin
14. 8609675 - Fused Tricyclic Compounds as novel mTOR inhibitors
15. 8591943 - Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors